{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T01:45:15Z","timestamp":1776303915803,"version":"3.50.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,5,24]],"date-time":"2018-05-24T00:00:00Z","timestamp":1527120000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1038\/s41409-018-0223-4","type":"journal-article","created":{"date-parts":[[2018,5,24]],"date-time":"2018-05-24T10:16:56Z","timestamp":1527157016000},"page":"304-307","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Decision analysis of up-front autologous hematopoietic stem cell transplantation in patients with peripheral T-cell lymphoma"],"prefix":"10.1038","volume":"54","author":[{"given":"Shigeo","family":"Fuji","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saiko","family":"Kurosawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro","family":"Inamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsunori","family":"Murata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takao","family":"Fuji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung-Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,5,24]]},"reference":[{"key":"223_CR1","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1182\/blood-2010-09-310342","volume":"117","author":"DD Weisenburger","year":"2011","unstructured":"Weisenburger DD, Savage KJ, Harris NL, Gascoyne RD, Jaffe ES, MacLennan KA, et al. Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. Blood. 2011;117:3402\u20138.","journal-title":"Blood"},{"key":"223_CR2","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1111\/bjh.14477","volume":"176","author":"D Chihara","year":"2017","unstructured":"Chihara D, Fanale MA, Miranda RN, Noorani M, Westin JR, Nastoupil LJ, et al. The survival outcome of patients with relapsed\/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma. Br J Haematol. 2017;176:750\u20138.","journal-title":"Br J Haematol"},{"key":"223_CR3","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1200\/JCO.2012.44.7524","volume":"31","author":"V Mak","year":"2013","unstructured":"Mak V, Hamm J, Chhanabhai M, Shenkier T, Klasa R, Sehn LH, et al. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. J Clin Oncol. 2013;31:1970\u20136.","journal-title":"J Clin Oncol"},{"key":"223_CR4","doi-asserted-by":"publisher","unstructured":"Fuji S, Kurosawa S, Inamoto Y, Murata T, Utsunomiya A, Uchimaru K et al. Role of up-front allogeneic hematopoietic stem cell transplantation for patients with aggressive adult T-cell leukemia-lymphoma: a decision analysis. Bone Marrow Transplant. 2018; https:\/\/doi.org\/10.1038\/s41409-017-0082-4 . [Epub ahead of print]","DOI":"10.1038\/s41409-017-0082-4"},{"key":"223_CR5","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1200\/JCO.2008.17.4870","volume":"27","author":"P Reimer","year":"2009","unstructured":"Reimer P, Rudiger T, Geissinger E, Weissinger F, Nerl C, Schmitz N, et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol. 2009;27:106\u201313.","journal-title":"J Clin Oncol"},{"key":"223_CR6","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","volume":"30","author":"F d\u2019Amore","year":"2012","unstructured":"d\u2019Amore F, Relander T, Lauritzsen GF, Jantunen E, Hagberg H, Anderson H, et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol. 2012;30:3093\u20139.","journal-title":"J Clin Oncol"},{"key":"223_CR7","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1093\/annonc\/mdx787","volume":"29","author":"G Fossard","year":"2017","unstructured":"Fossard G, Broussais F, Coelho I, Bailly S, Nicolas-Virelizier E, Toussaint E, et al. Role of up-front autologous stem cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers. Ann Oncol. 2017;29:715\u201323.","journal-title":"Ann Oncol"},{"key":"223_CR8","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1093\/annonc\/mdl466","volume":"18","author":"J Rodriguez","year":"2007","unstructured":"Rodriguez J, Conde E, Gutierrez A, Arranz R, Leon A, Marin J, et al. The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience. Ann Oncol. 2007;18:652\u20137.","journal-title":"Ann Oncol"},{"key":"223_CR9","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.bbmt.2008.11.010","volume":"15","author":"DH Yang","year":"2009","unstructured":"Yang DH, Kim WS, Kim SJ, Bae SH, Kim SH, Kim IH, et al. Prognostic factors and clinical outcomes of high-dose chemotherapy followed by autologous stem cell transplantation in patients with peripheral T cell lymphoma, unspecified: complete remission at transplantation and the prognostic index of peripheral T cell lymphoma are the major factors predictive of outcome. Biol Blood Marrow Transplant. 2009;15:118\u201325.","journal-title":"Biol Blood Marrow Transplant"},{"key":"223_CR10","doi-asserted-by":"publisher","first-page":"8507","DOI":"10.1200\/JCO.2015.63.1143","volume":"33","author":"N Schmitz","year":"2015","unstructured":"Schmitz N, Nickelsen M, Altmann B, Ziepert M, Bouabdallah K, Gisselbrecht C, et al. Allogeneic or autologous transplantation as first-line therapy for younger patients with peripheral T-cell lymphoma: Results of the interim analysis of the AATT trial. J Clin Oncol. 2015;33:8507\u20138507.","journal-title":"J Clin Oncol"},{"key":"223_CR11","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.3324\/haematol.2017.164996","volume":"102","author":"S Fuji","year":"2017","unstructured":"Fuji S, Yamaguchi T, Inoue Y, Utsunomiya A, Moriuchi Y, Uchimaru K, et al. Development of a modified prognostic index for patients with aggressive adult T-cell leukemia-lymphoma aged 70 years or younger: possible risk-adapted management strategies including allogeneic transplantation. Haematologica. 2017;102:1258\u201365.","journal-title":"Haematologica"},{"key":"223_CR12","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1182\/blood.V106.11.2679.2679","volume":"106","author":"S Horwitz","year":"2005","unstructured":"Horwitz S, Moskowitz C, Kewalramani T, Hamlin P, Straus D, O\u2019Connor O, et al. Second-line therapy with ICE followed by high dose therapy and autologous stem cell transplantation for relapsed\/refractory peripheral T-cell lymphomas: minimal benefit when analyzed by intent to treat. Blood. 2005;106:2679.","journal-title":"Blood"},{"key":"223_CR13","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.clml.2013.07.005","volume":"13","author":"N Mehta","year":"2013","unstructured":"Mehta N, Maragulia JC, Moskowitz A, Hamlin PA, Lunning MA, Moskowitz CH, et al. A retrospective analysis of peripheral T-cell lymphoma treated with the intention to transplant in the first remission. Clin Lymphoma Myeloma Leuk. 2013;13:664\u201370.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"223_CR14","doi-asserted-by":"crossref","unstructured":"Hsu YT, Tsai HJ, Chang JS, Li SS, Tang JL, Yeh SP, et al. Stem cell transplantation for T-cell lymphomas in Taiwan. Bone Marrow Transplant. 2018.","DOI":"10.1038\/s41409-018-0116-6"},{"key":"223_CR15","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1002\/ajh.24372","volume":"91","author":"C Yam","year":"2016","unstructured":"Yam C, Landsburg DJ, Nead KT, Lin X, Mato AR, Svoboda J, et al. Autologous stem cell transplantation in first complete remission may not extend progression-free survival in patients with peripheral T cell lymphomas. Am J Hematol. 2016;91:672\u20136.","journal-title":"Am J Hematol"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41409-018-0223-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-018-0223-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-018-0223-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:12:17Z","timestamp":1684617137000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-018-0223-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,24]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["223"],"URL":"https:\/\/doi.org\/10.1038\/s41409-018-0223-4","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,24]]},"assertion":[{"value":"1 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"S.F. received honoraria from Kyowa Hakko Kirin Co., Ltd. T.M. is an employee of Crecon Medical Assessment Inc, Tokyo, Japan, The remaining authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}